**Bruker Corporation Reports Fiscal Year 2025 Results**
Bruker Corporation (BRKR) reported total revenue of $3.437 billion for the fiscal year ended December 31, 2025, an increase of 2.1% compared to $3.366 billion in 2024. The company's gross profit was $1.578 billion, representing a gross profit margin of 45.9%, down from $1.650 billion and 49.0% respectively in the previous year. Operating income decreased significantly to $68.2 million, a margin of 2.0%, compared to $253.1 million and 7.5% in 2024. The company reported a net loss attributable to Bruker Corporation common shareholders of $22.5 million, or $0.15 per diluted share, compared to net income of $113.1 million, or $0.76 per diluted share, in the prior year.
The company experienced varying performance across its segments. BSI BioSpin revenue decreased by 3.0%, while BSI CALID revenue increased by 10.7%. BSI NANO revenue decreased by 1.3%, and BEST revenue decreased by 4.3%. The overall revenue increase was primarily driven by the ELITechGroup and NanoString acquisitions, offsetting organic revenue decline. The company's operating income was negatively impacted by unfavorable revenue mix, increased restructuring costs, impairment charges, U.S. tariffs, and foreign exchange headwinds.
Strategic developments during the year included the acquisitions of Recipe Chemicals + Instruments GmbH and AST Revolution, LLC, enhancing capabilities in clinical diagnostic assays and antimicrobial susceptibility testing, respectively. The company also completed certain minority investments to expand technological capabilities and product portfolios. Bruker launched the MOVE-T solution for dairy markets and the VERTEX NEO R FTIR research spectrometer, along with new technologies and workflows advancing proteomics and multiomics in Mass Spectrometry.
Bruker's backlog increased to $2.569 billion as of December 31, 2025, compared to $2.090 billion in 2024, primarily driven by higher BEST order bookings. The company employed approximately 11,085 people worldwide as of December 31, 2025, with 20.2% located in the United States. The company is implementing a cost savings initiative aimed at reducing annualized costs by $100 million to $120 million by the end of 2026.
About BRUKER CORP
Bruker Corporation develops, manufactures, and distributes high-performance scientific instruments and analytical solutions for life and materials science research, biopharmaceuticals, diagnostics, and applied markets. Its core technologies include magnetic resonance, mass spectrometry, chromatography, X-ray, microscopy, and molecular spectroscopy. Serving academic, government, industrial, and clinical customers worldwide, Bruker offers integrated hardware, software, and services that enable molecular and cellular analysis, supporting innovation and productivity across diverse scientific fields.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.